## AMENDMENTS TO THE SPECIFICATION

Please insert before line 5, page 1 the following:

# CROSS REFERENCED RELATED APPLICATION

This application is a National Stage International Application No. PCT/JP03/17031, filed December 26, 2003, which claimed priority to Japanese application 375892/2002, filed on December 26, 2002, both of which are hereby incorporated by reference in their entirety.

Please amend line 10, page 1 as follows:

## [BACKGROUND ARTOF THE INVENTION]

Please replace the paragraph that begins on line 15, page 2 as follows:

In the treatment of pemphigoid typified by BP, external use of corticosteroids has so far been performed for erythema as a dermal symptom, and external use of <a href="EKSALB@Eksalb">EKSALB@Eksalb</a> (registered trademark) or zinc oxide ointment (unguentum simplex) has been performed for erosion. Since external use of such drugs alone has proved insufficient in efficacy, however, oral administration of tetracycline antibiotics (Minomycin MINOMYCIN® (registered trademark), <a href="ACHROMYCIN® Achromycin (registered trademark)">ACHROMYCIN® Achromycin (registered trademark)</a>), nicotinamide, and corticosteroids has been implemented for systemic administration. If these treatments are still ineffective, systemic administration of immunosuppressants or plasmapheresis has been carried out. For pruritus, antihistaminics or antiallergic drugs have been administered as symptomatic therapies.

Please amend line 13, page 3 as follows:

#### **Disclosure of Invention**

Please amend line 1, page 5 as follows:

#### [SUMMARY OF THE INVENTIONMEANS FOR SOLVING THE PROBLEMS]

Please amend line 22, page 6 as follows:

[MODES FOR CARRYING OUT THE INVENTION DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS]

Please replace the paragraph that begins on line 23, page 6 as follows:

IFN-γ used in the present invention may be that of the natural or recombinant gene type, such as IFN-γ1a (interferon gamma-1a), IFN-γ1b (interferon gamma-1b), and IFN-γn1 (interferon gamma-n1). However, IFN-γ of the recombinant gene type is preferred as a stable source of supply. For example, Biogamma (registered trademark)BIOGAMMA®